|
Performance characteristics of a tumor-informed circulating tumor DNA (ctDNA) minimal residual disease (MRD) assay in invasive bladder cancer in clinical practice. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca |
|
|
Honoraria - HMP; OncLive; OneOncology |
Consulting or Advisory Role - AVEO; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; Immunomedics; Seagen |
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Compugen (Inst); Exelixis (Inst); Merck (Inst); OBI Pharma (Inst); Roche/Genentech (Inst); Seagen (Inst); Tizona Therapeutics, Inc. (Inst) |
Travel, Accommodations, Expenses - Caris Life Sciences; Tempus |
|
|
Honoraria - Aptitude Health; Elsevier; IMEDEX |
Consulting or Advisory Role - Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Genentech/Roche; Lilly (Inst); OBI Pharma |
Research Funding - Array BioPharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bayer; Genentech/Roche |
|
|
No Relationships to Disclose |